EUCTR2005-002206-37-DE
Active, Not Recruiting
N/A
Multicenter phase I/II study of radioimmunotherapy with 90Y-ibritumomab tiuxetan in a nonmyeloablative conditioning regimen for allogeneic hematopoietic cell transplantation from HLA-identical donors in patients with advanced non-Hodgkin lymphoma
Medizinische Universitätsklinik II , Abteilung Hämatologie, Onkologie, Immunologie und Rheumatologie0 sites40 target enrollmentSeptember 27, 2005
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Medizinische Universitätsklinik II , Abteilung Hämatologie, Onkologie, Immunologie und Rheumatologie
- Enrollment
- 40
- Status
- Active, Not Recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Following entities of lymphomas can be included in Arm A of the protocol:
- •\- Small lymphocytic lymphoma (SLL/CLL)
- •\- Mantle cell lymphoma (MCL)
- •\- Follicular lymphoma Grade 1\-2
- •\- Marginal zone lymphoma (MZL)
- •\- Extranodal (MALT lymphoma)
- •\- Nodal (Monocytoid B\-cell lymphoma)
- •Following lymphoma entities can be included in Arm B of the protocol:
- •\- Diffuse large B\-cell lymphoma/Follicular lymphoma grade 3
- •\- Grade 3 follicular lymphoma
Exclusion Criteria
- •\- Patients with rapidly progressive disease
- •\- Less than 3 months after preceding HCT
- •\- CNS involvement with disease
- •\- Fungal infections with radiological progression after receipt of amphotericin B or
- •active triazole for greater than 1 month.
- •\- Liver function abnormalities with bilirubin \>2 mg/dL and elevation of transaminases
- •higher 2x upper limit of normal.
- •\- Chronic active viral hepatitis
- •\- Ejectionfraction \<40 % on echocardiography
- •\- Patients with \> grade II hypertension by CTC criteria
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin LymphomaNon-Hodgkin LymphomaNCT00302757University Hospital Tuebingen60
Active, Not Recruiting
N/A
Phase II multicenter study of immuno-chemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for symptomatic Waldenstrom's macroglobulinemiaEUCTR2005-000174-52-ITASSOCIAZIONE MALATTIE SANGUE
Recruiting
Phase 1
Phase I study for simultaneous radiochemotherapy of relapsed ovarian cancerC51-C58Malignant neoplasms of female genital organsDRKS00008552niversitätsklinikum für Strahlentherapie6
Active, Not Recruiting
N/A
A Phase I/IIa (early phase) Study of Targeted Radiotherapy alone for Stem Cell Transplant Conditioning in Systemic AL AmyloidosisEUCTR2015-002231-18-GBniversity Southampton Hospital NHS Foundation Trust18
Completed
Phase 1
Targeted radiotherapy for AL-Amyloidosis – TRALASystemic AL-AmyloidosisNutritional, Metabolic, EndocrineAmyloidosisISRCTN13400668niversity Hospital Southampton NHS Foundation Trust10